OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
Fátima Cardoso, Shani Paluch‐Shimon, Eva Schumacher-Wulf, et al.
The Breast (2024) Vol. 76, pp. 103756-103756
Open Access | Times Cited: 29
Fátima Cardoso, Shani Paluch‐Shimon, Eva Schumacher-Wulf, et al.
The Breast (2024) Vol. 76, pp. 103756-103756
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
Breast cancer: pathogenesis and treatments
Xin Xiong, Lewei Zheng, Yu‐Qiang Ding, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Xin Xiong, Lewei Zheng, Yu‐Qiang Ding, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Complete and Durable Remission in Metastatic Breast Cancer with Liver Metastases Using a Combination of Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor: What About Therapeutic De-Escalation?
Choukri Elm’hadi, Meryem Zerrik, Rachid Tanz
Indian Journal of Gynecologic Oncology (2025) Vol. 23, Iss. 1
Closed Access
Choukri Elm’hadi, Meryem Zerrik, Rachid Tanz
Indian Journal of Gynecologic Oncology (2025) Vol. 23, Iss. 1
Closed Access
Antibody-Drug conjugates In elderly patients With Breast Cancer
Marta Bonotto, G Pieri, Rocco Esposto, et al.
The Breast (2025) Vol. 80, pp. 104428-104428
Open Access
Marta Bonotto, G Pieri, Rocco Esposto, et al.
The Breast (2025) Vol. 80, pp. 104428-104428
Open Access
Interaction between redox regulation, immune activation, and response to treatment in HER2+ breast cancer
Paulo Luz, Sofı́a Ramos, Maria José Oliveira, et al.
Redox Biology (2025), pp. 103609-103609
Open Access
Paulo Luz, Sofı́a Ramos, Maria José Oliveira, et al.
Redox Biology (2025), pp. 103609-103609
Open Access
PROGNOSTIC SIGNIFICANCE OF TR53 GENE MUTATION IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER
О. І. Vynnychenko, Yuliia Moskalenko, Anastasiia Denysenko, et al.
Art of Medicine (2025), pp. 12-19
Closed Access
О. І. Vynnychenko, Yuliia Moskalenko, Anastasiia Denysenko, et al.
Art of Medicine (2025), pp. 12-19
Closed Access
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting
Hope S. Rugo, Rachel M. Layman, Filipa Lynce, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104103-104103
Open Access
Hope S. Rugo, Rachel M. Layman, Filipa Lynce, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104103-104103
Open Access
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes
Gaia Griguolo, Michele Bottosso, A Crema, et al.
European Journal of Cancer (2025) Vol. 219, pp. 115321-115321
Open Access
Gaia Griguolo, Michele Bottosso, A Crema, et al.
European Journal of Cancer (2025) Vol. 219, pp. 115321-115321
Open Access
The SONIA trial shows the power and challenges of academic research
Shani Paluch‐Shimon, Fátima Cardoso
Nature Reviews Clinical Oncology (2025)
Closed Access
Shani Paluch‐Shimon, Fátima Cardoso
Nature Reviews Clinical Oncology (2025)
Closed Access
Prevention of Sacituzumab Govitecan-Related Neutropenia and Diarrhea in Patients with Her2-Negative Advanced Breast Cancer (PRIMED): An Open-Label, Single-Arm, Phase 2 Trial
José Manuel Pérez-García, María Gión, Manuel Ruíz Borrego, et al.
(2025)
Closed Access
José Manuel Pérez-García, María Gión, Manuel Ruíz Borrego, et al.
(2025)
Closed Access
18 F-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer
David Groheux, Sofia C. Vaz, Lioe‐Fee de Geus‐Oei, et al.
Journal of Clinical Oncology (2025)
Closed Access
David Groheux, Sofia C. Vaz, Lioe‐Fee de Geus‐Oei, et al.
Journal of Clinical Oncology (2025)
Closed Access
Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer
Masakazu Toi
Breast Cancer (2025)
Closed Access
Masakazu Toi
Breast Cancer (2025)
Closed Access
Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it
Frédéric Lecouvet, Caroline Chabot, Lokmane Taihi, et al.
Skeletal Radiology (2024) Vol. 53, Iss. 9, pp. 1815-1831
Open Access | Times Cited: 3
Frédéric Lecouvet, Caroline Chabot, Lokmane Taihi, et al.
Skeletal Radiology (2024) Vol. 53, Iss. 9, pp. 1815-1831
Open Access | Times Cited: 3
Molecular Targets of Minor Cannabinoids in Breast Cancer: In Silico and In Vitro Studies
Cristina Ferreira Almeida, Andreia Palmeira, Maria João Valente, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1245-1245
Open Access | Times Cited: 2
Cristina Ferreira Almeida, Andreia Palmeira, Maria João Valente, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1245-1245
Open Access | Times Cited: 2
Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines
David Groheux, Sofia C. Vaz, Philip Poortmans, et al.
The Breast (2024) Vol. 78, pp. 103806-103806
Open Access | Times Cited: 1
David Groheux, Sofia C. Vaz, Philip Poortmans, et al.
The Breast (2024) Vol. 78, pp. 103806-103806
Open Access | Times Cited: 1
Survey on adverse events associated with drug therapy for breast cancer patients
Fumikata Hara, Reiko Nagasaki, Reiko Minami, et al.
BMC Women s Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Fumikata Hara, Reiko Nagasaki, Reiko Minami, et al.
BMC Women s Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Inflammatory breast cancer microenvironment repertoire based on DNA methylation data deconvolution reveals actionable targets to enhance the treatment efficacy
Naiade Calanca, Flávia Lima Costa Faldoni, Cristiano Pádua Souza, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Naiade Calanca, Flávia Lima Costa Faldoni, Cristiano Pádua Souza, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer
Laia Garrigós, Daniela Camacho, José Manuel Pérez-García, et al.
Expert Review of Anticancer Therapy (2024), pp. 1-10
Closed Access
Laia Garrigós, Daniela Camacho, José Manuel Pérez-García, et al.
Expert Review of Anticancer Therapy (2024), pp. 1-10
Closed Access
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer
Ayumu Mitsuyoshi, Masayuki Nagahashi, Haruka Kanaoka, et al.
International Journal of Clinical Oncology (2024)
Closed Access
Ayumu Mitsuyoshi, Masayuki Nagahashi, Haruka Kanaoka, et al.
International Journal of Clinical Oncology (2024)
Closed Access
Hematological toxicities of cyclin-dependent kinase 4 and 6 inhibitors in metastatic breast cancer: Single institution experience
Slobodan Kutić, Marijana Milović-Kovačević, Teodora Novaković, et al.
Srpski medicinski casopis Lekarske komore (2024) Vol. 5, Iss. 3, pp. 320-330
Open Access
Slobodan Kutić, Marijana Milović-Kovačević, Teodora Novaković, et al.
Srpski medicinski casopis Lekarske komore (2024) Vol. 5, Iss. 3, pp. 320-330
Open Access
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer
Philipp Zimmer, Tobias Esser, Diana Lueftner, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access
Philipp Zimmer, Tobias Esser, Diana Lueftner, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial
Eriko Tokunaga, Hiroji Iwata, Mitsuya Itoh, et al.
Breast Cancer (2024)
Open Access
Eriko Tokunaga, Hiroji Iwata, Mitsuya Itoh, et al.
Breast Cancer (2024)
Open Access
Treatment Strategies and Sequencing After Endocrine Therapy Plus CDK4/6 Inhibitors in Patients with ER+/HER2- Advanced/Metastatic Breast Cancer
Nicola Humphry
EMJ Oncology (2024), pp. 27-38
Open Access
Nicola Humphry
EMJ Oncology (2024), pp. 27-38
Open Access
Protein biomarkers for subtyping breast cancer and implications for future research: a 2024 update
Claudius Mueller, Justin B. Davis, Virginia Espina
Expert Review of Proteomics (2024) Vol. 21, Iss. 9-10, pp. 401-416
Closed Access
Claudius Mueller, Justin B. Davis, Virginia Espina
Expert Review of Proteomics (2024) Vol. 21, Iss. 9-10, pp. 401-416
Closed Access
Primary Tumor Resection in De Novo Metastatic Breast Cancer from an Oligometastatic Perspective: A Systematic Review and Meta-analysis
Chen Wu, Li Xiang, Shiyang Liu, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111224-111224
Open Access
Chen Wu, Li Xiang, Shiyang Liu, et al.
iScience (2024) Vol. 27, Iss. 12, pp. 111224-111224
Open Access
The effective duration of systemic therapy and the neutrophil-to-lymphocyte ratio predict the surgical advantage of primary tumor resection in patients with de novo stage IV breast cancer: a retrospective study
Rie Sugihara, Hidetaka Watanabe, S Matsushima, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access
Rie Sugihara, Hidetaka Watanabe, S Matsushima, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access
